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Abstract Genome sequencing and gene expression analyses of prostate 
tumours have highlighted the potential importance of genetic and epigenetic 
changes observed in WNT signalling pathway components in prostate tumours, 
particularly in the development of castration-resistant prostate cancer. WNT 
signalling is also important in the prostate tumour microenvironment, where 
WNT proteins secreted by the tumour stroma promote therapy resistance, and 
in prostate cancer stem or progenitor cells, where WNT-b-catenin signals 
promote self-renewal or expansion. Preclinical studies have demonstrated the 
potential of inhibitors that target WNT-receptor complexes at the membrane or 
that block the interaction of b-catenin with LEF1 and the androgen receptor, in 
preventing prostate cancer progression. Some Wnt signalling inhibitors are in 
Phase I trials, but they have yet to be tested in patients with prostate cancer. 
 
Prostate cancer was the most commonly diagnosed cancer and second leading 
cause of cancer death in men in the USA in 20161. Androgen deprivation 
therapy (ADT) is the standard of care for men with prostate cancer, owing to 
the essential role of the androgen receptor (AR) in the normal growth and 
development of the prostate gland, as well as in prostate carcinogenesis2,3,4. 
Unfortunately, most tumours progress to an aggressive state, known as 
castration-resistant prostate cancer (CRPC), despite ADT5–7. Several 
mechanisms, most of which are AR-dependent, are involved in the 
development of resistance. These mechanisms include the amplification and/or 
mutation of AR, expression of AR splice variants, increased production of 
androgens, and changes in the activity or expression of AR coactivators and 
corepressors7–9. However, other, often AR-independent, signals have been 
implicated in the acquisition of resistance, among them are those triggered by  
WNT family proteins10. 	This Review focuses on new findings since our last review of the topic in 
201211. These data demonstrate that the field of WNT signalling research has 
progressed both at the level of basic research, in which noncanonical WNT 
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signalling is now recognized as an important contributor to prostate cancer 
progression and new regulators of canonical WNT signalling at the plasma 
membrane have been identified, and at the clinical level, where WNT signalling 
might soon receive approval for clinical use, as WNT signalling inhibitors are 
now in early stage clinical trials12–34 (Table 2). 
 
[H1] An overview of WNT signalling 
 The WNT family comprises 19 cysteine-rich, secreted lipoglycoproteins that 
have fundamental roles during embryonic and organ development by regulating 
stem cell self-renewal and cell proliferation, migration, and differentiation35–37. 
WNTs bind to transmembrane frizzled (FZD) receptors and a variety of 
coreceptors, including low-density lipoprotein receptor (LRP)4 to LRP6, 
tyrosine-protein kinase transmembrane receptor ROR1 and ROR2, and 
tyrosine-protein kinase RYK (RYK)38 to activate canonical (β-catenin-
dependent) and noncanonical (β-catenin-independent) signals (Fig. 1). 
 A hallmark of canonical WNT signalling is the stabilization and nuclear 
translocation of the protein β-catenin. In the absence of WNT ligands, β-catenin 
is recruited and degraded by the destruction complex, whose components 
include axin, glycogen synthase kinase-3 (GSK-3), casein kinase 1 (CK1) and 
adenomatous polyposis coli protein (APC). WNT binding to FZD receptors and 
LRP5 and LRP6 coreceptors results in the phosphorylation of the latter by CK1 
and GSK-3 and recruitment of axin and dishevelled (DVL) to the plasma 
membrane, thereby disrupting the destruction complex. This disruption results 
in the stabilization of β-catenin, which accumulates in the cytoplasm and enters 
the nucleus, binding to T-cell factor/lymphoid enhancer-binding factor 1 
(TCF/LEF) family transcription factors and coactivators, such as the CREB-
binding protein (CBP)–histone acetyltransferase p300 (p300 HAT) family and 
B-cell lymphoma 9 protein (BCL9) and B-cell lymphoma 9-like protein (BCL9L), 
and regulating the expression of WNT target genes39 (Fig. 1). 
A novel branch of WNT signalling, WNT-dependent stabilization of proteins 
(WNT–STOP)40, was described in 2014. In this signalling cascade, the signal 
is initiated by WNT binding to LRP6 but the effects are transcription-
independent, involving cyclin-Y, rather than b-catenin40. WNT–STOP signals 
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promote protein stabilization at mitosis. The targets are involved cell-cycle 
progression, endolysosomal biogenesis, DNA remodelling and the 
cytoskeleton, so WNT-STOP signals could be important in cancer initiation and 
progression41	(Fig. 1). 
 Noncanonical WNT signals are less well defined than canonical signals. 
Noncanonical signals are traditionally subdivided into planar cell polarity (PCP) 
and WNT–Ca2+	pathways39, although additional b-catenin- and TCF-
independent signals also exist42. Noncanonical WNT signals are activated upon 
WNT binding to FZD receptors and tyrosine-kinase-like coreceptors, resulting 
in the recruitment and activation of DVL. The PCP pathway has two parallel 
branches involving small GTPases: Rho, which activates Rho-associated 
kinase (ROCK) and Rac, which is linked to c-Jun-N-terminal kinase (JNK), and 
signalling by activator protein 1 (AP-1) family transcription factors. Cytoskeletal 
and transcriptional changes associated with these small GTPases regulate cell 
adhesion and migration39,42–44. Activation of the WNT–Ca2+	pathway stimulates 
Ca2+	release from the endoplasmic reticulum, promoting activation of G-
proteins, protein kinase C (PKC)	and Ca2+/calmodulin-dependent kinase type II 
(CaMKII). These events can also result in the activation of transcription factors, 
such as nuclear factor of activated T-cells (NFAT), which promotes cell growth, 
survival, invasion, and angiogenesis42,43,45,46 (Fig. 1). 
 In 2010, novel associations were identified between WNT and Hippo signalling, 
which regulates organ size, tissue homeostasis, and patterning47. Hippo signals 
are transduced by yes-associated protein	 (YAP), transcriptional coactivator 
with PDZ-binding motif	 (TAZ), and TEA domain family transcription factors	(TEADs)48. YAP-TAZ signals antagonize canonical WNT signalling by binding 
to components of the destruction complex, such as axin49, and regulating 
nuclear translocation of b-catenin (Fig.1). In addition, a noncanonical WNT–
YAP-TAZ signalling axis has been described, in which WNT binding to FZD and 
ROR activates Ga12, Ga13, Rho, and large tumour suppressor homolog (LATS)1 
and LATS2 to induce YAP-TAZ signals and TEAD-dependent transcription50. 
The importance of this alternative WNT signalling pathway in prostate cancer 
is yet to be examined. 
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 The specific mechanisms by which WNT proteins stimulate these different 
responses are not fully elucidated, but are anticipated to involve the binding 
and activation of distinct WNT receptors51,52. FZD family receptors have a role 
in most WNT signalling pathways. These seven-pass transmembrane proteins 
have an extracellular, cysteine-rich domain (CRD) that is essential and 
sufficient for WNT binding53–55. The crystal structure of the mouse Fzd8 CRD 
bound to Xenopus Wnt-8 shows the ligand resembling a hand with the thumb 
and index finger grasping the receptor. The thumb´s palmitoleic acid group 
projects into a deep groove in the CRD (Site 1) while the finger interacts with a 
small depression in the CRD (Site 2)56 (Fig.2). The lipid thumb domain of Wnt-
8 interacts with residues conserved among FZD family members, accounting 
for the promiscuity of WNT-FZD interactions. On the other hand, some Site 2 
residues are not conserved, Met149, for example, is present in 5 of 10 
mammalian FZD proteins56, suggesting that Site 2 interactions are responsible 
for binding specificity56. The structure also suggested a potential binding site 
for WNT coreceptors: a conserved solvent-exposed patch of 10 residues on the 
opposite side of Wnt-8 to	the FZD-binding site56,38 (Fig.2). Additional insight into 
WNT-FZD interactions comes from two independent structural studies of FZD 
CRDs in complex with fatty acids, which show that the acyl group promotes 
FZD CRD dimerization and support a 1:2 stoichiometry model for WNT-FZD 
complexes57,58. Moreover, palmitoylated WNT-5A and WNT-8A stabilize the 
FZD4-CRD-CRD interaction, suggesting that FZD receptors form signalosomes 
(multiprotein complexes containing membrane-localized Wnt receptors and 
cytosolic protein complexes containing AXIN and DVL capable of transmitting 
the WNT signal) upon WNT binding and that the WNT palmitoleoyl group is 
crucial for this interaction57. Additional studies will be required to determine how 
these interactions orchestrate WNT signalosome assembly. 
 Apart from FZD receptors, the single-pass transmembrane WNT receptors 
LRP5 and LRP6 are best known for transducing b-catenin-dependent signals. 
These receptors form a trimeric complex with WNT and FZD that is essential 
for activation of the canonical pathway38,55. By contrast, ROR1 and ROR2 have 
CRDs related to the FZD CRD and activate noncanonical signals38,42,59. In 
addition, RYK binds WNT proteins via a WNT inhibitory factor (WIF) domain 
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and is implicated in canonical and noncanonical signalling38,59, and protein-
tyrosine kinase 7 (PTK7); also known as colon carcinoma kinase 4 (CCK4), 
which is involved in the PCP pathway and has a less well-defined WNT binding 
site than RYK, ROR1 and ROR260. ROR1, ROR2, RYK, and PTK7 have 
intracellular tyrosine-kinase-like domains but they are most likely 
pseudokinases because these domains lack key residues found at the catalytic 
site of active kinases and they are devoid of detectable kinase activity in in vitro 
assays. Although it remains possible that the conditions for their catalytic 
activation have not been found, it is more likely that they function in association 
with FZDs, other WNT receptors and allosteric activation of intracellular and 
other receptor tyrosine kinases59,61,62. By contrast, the ROR-related kinase, 
muscle, skeletal receptor tyrosine-protein kinase (MuSK), which also binds 
WNTs via a CRD, is catalytically active38, as is CAM-1, the Caenorhabditis 
elegans ROR homolog, suggesting that the signalling mechanisms of this 
family of kinases have diverged. 	
 Regulation of WNT signalling by secreted WNT antagonists is more complex 
than that of the receptors. These antagonists can be divided into two classes: 
those that bind WNT proteins, such as secreted frizzled-related proteins 
(sFRPs), WIF-1 and Cerberus, and those that associate with the WNT 
coreceptors LRP5 and LRP6, namely Dickkopf-related protein (DKK)-1, DKK-
2, and DKK-463–65. DKK-3 is a unique member of this family that does not bind 
LRP5 or LRP6, but can affect WNT signalling indirectly65. Adding further 
complexity, sFRPs can also bind to FZD receptors and activate or inhibit WNT 
signalling63,66. 
 Results of studies published between 2013 and 2016 have revealed additional 
mechanisms of regulation of WNT signalling at the cell membrane64,65,67. The 
transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 inhibit WNT signalling 
by targeting FZD receptors for ubiquitination and degradation. ZNRF3 and 
RNF43, in turn, are regulated by R-spondins (RSPO1–RSPO4), which are 
secreted proteins that enhance WNT signalling by simultaneously binding 
ZNRF3 and RNF43 and leucine-rich repeat-containing G protein-coupled 
receptors (LGR4–LGR6) to promote ubiquitination and membrane clearance of 
ZNRF3 and RNF43, facilitating FZD receptor stabilization67,68 (Fig. 3).	
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[H1] WNT signalling pathway alterations 
 Dysregulation of the WNT signalling pathway has been observed in several 
types of cancer, and some major alterations have been found in prostate cancer 
in the past 5 years (Table 1)10,11,35,69. 
[H2] Canonical effectors 
  b-catenin is the key effector of the canonical WNT pathway. The stability of  b-
catenin is tightly regulated by a destruction complex of associated proteins, 
including axin and APC, which promotes its phosphorylation, ubiquitination, and 
degradation; the presence of cytoplasmic and/or nuclear b-catenin provides an 
indication of dysregulation. By contrast, the pool of b-catenin at the plasma 
membrane is protected from degradation by its interaction with cadherins. A 
considerable proportion of prostate tumours have increased levels of b-catenin 
in the cytoplasm and/or nucleus either as a result of gene mutations, or, more 
frequently, nongenomic changes in the expression of inhibitors and activators 
of WNT signalling11. 
 Activating mutations in the gene encoding b-catenin (CTNNB1) and 
inactivating mutations in the genes that encode proteins in the destruction 
complex (APC and AXIN1) increase WNT–b-catenin signalling in many types 
of cancer, particularly colorectal cancer, but are infrequent in prostate 
cancer10,11. However, genetic and epigenetic changes have been discovered 
that activate WNT–b-catenin signalling and could, therefore, contribute to 
prostate cancer progression. Genetic changes that activate  WNT–b-catenin 
signalling are more frequently observed in castration-resistant prostate cancer 
(CRPC) than in treatment-naive prostate cancer. Recurrent alterations in 
CTNNB1 were observed in 12% of CRPC samples70. Comparison of CRPC and 
high-grade, untreated, localized prostate tumours uncovered alterations in APC 
in 22% of lethal, castration-resistant tumours and in none of the untreated 
tumours71, and a multi-institutional study of 150 metastatic CRPC tumours 
revealed genomic alterations affecting APC and CTNNB1 in 18% of samples72. 
In addition, analysis of single nucleotide polymorphisms (SNPs) in WNT 
pathway genes identified links between gene variants of APC and reduced 
PSA-free survival73 and prostate cancer progression74. 
 A variety of cell systems and mouse models have been used to determine the 
	 8	
outcome of b-catenin stabilization in non-malignant prostate cells and prostate 
cancer cells10,11. Studies in mice show that genetic activation of WNT–b-catenin 
signalling by a stabilized form of b-catenin or by Apc deletion results in high-
grade prostate intraepithelial neoplasia (PIN). However, progression to invasive 
carcinoma requires a second event, for example, overexpression of serine 
protease hepsin75 or deletion of phosphatase and tensin homolog (PTEN)76. 
 Association of b-catenin with binding partners in the nucleus, such as TCF/LEF 
family transcription factors, protects b-catenin from the destruction complex by 
competing with APC and axin for binding to the b-catenin armadillo repeat 
domain, as is the case at the plasma membrane. All four TCF/LEF family 
members are expressed to varying extents in the prostate and in prostate 
tumours, but LEF1 has been the focus of most studies, as it is upregulated in 
androgen-independent tumours77. LEF1 is a WNT-b-catenin target gene and 
also a target gene of transcriptional regulator ERG (ERG), which is upregulated 
in ~50% of prostate tumours 78. A 2016 study comparing b-catenin and LEF1 
levels in prostate tumour microarray samples (TMAs) showed increases in the 
proportion of cells coexpressing b-catenin and LEF1 in localized prostate 
cancer and in tumour metastases, which suggests a role for β-catenin–LEF1-
mediated transcription in both malignant transformation and metastasis of 
prostate cancer79.  
 TCF/LEF family members are the key mediators of b-catenin-dependent 
transcription, other transcription factors interact with b-catenin in specific cell 
types and tissues. The AR is a crucial partner for b-catenin in prostate cancer. 
Given the influence of AR in prostate cancer, the importance and 
consequences of this interaction have been studied in detail11,80,81. 
Coexpression of AR and cytoplasmic b-catenin in patient tumour samples 
correlates with high primary Gleason grade (4-5), disease progression, and 
PSA levels in patients82, and AR and WNT signalling pathways are enriched in 
patients with early-onset (diagnosed at < 50 years of age) prostate cancer83. 
 In mice, the overexpression of AR and stabilized b-catenin in prostate epithelial 
cells accelerates tumour development and invasion and reduces survival, 
suggesting that increased AR signalling enhances b-catenin-mediated prostate 
tumour initiation84. Castration of these mice resulted in tumour regression, 
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implying that AR signalling is also required for tumour maintenance84. If and 
how AR signalling and b-catenin-dependent signalling work together is not well 
understood. In this mouse study, both AR and b-catenin were recruited to 
regions of the myc proto-oncogene protein (c-Myc) locus containing TCF/LEF 
family transcription factor binding sites84. In addition, gene expression 
microarray analysis showed that AR overexpression potentiated expression of 
some genes induced by stabilized b-catenin, including Myc, Spp1, and Egr1, 
which promote metastasis. However, it also reduced expression of the direct b-
catenin gene targets Lef1 and Axin284, consistent with previous studies in 
human cells showing competition between TCF/LEF family transcription factors 
and AR for binding to b-catenin10,11. The interactions among AR, b-catenin, and 
TCF/LEF family transcription factors can be affected by the activation state of 
AR, with hormone deprivation or treatment with the antiandrogen enzalutamide 
redirecting b-catenin from AR to TCF-4, leading to activation of WNT–β-catenin 
signalling85. These observations highlight the pathophysiological relevance and 
the complexity of the link between AR and WNT–b-catenin signalling in prostate 
cancer and suggest that a combination of antiandrogens and WNT inhibitors 
could improve the effectiveness of current treatments targeting the AR85. Other 
nuclear proteins might also activate WNT–β-catenin signalling in hormone-
deprived cells, such as the nuclear form of the tyrosine-protein kinase MET, 
nMET86, and transcription factor SOX (SOX)-487,88. 	
[H1] WNT ligands and their receptors 
 The low frequency of WNT signalling pathway gene mutations in the majority 
of prostate tumours has encouraged the study of upstream components of the 
pathway. Novel molecular mechanisms have been discovered that stabilize 
WNT receptors at the membrane to sustain WNT signals. However, these 
receptors still require the presence of WNT ligands, the study of which has been 
hampered by their low expression and/or the lack of specific antibodies. For 
example, gene expression analysis indicates that WNT1 mRNA is low or 
undetectable in prostate cancer cell lines 78,89,90, lower in organ confined (pT2) 
and non-organ confined (pT3/4) tumours than in benign prostatic hyperplasia, 
and highly expressed in advanced prostate cancer90, whereas 
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immunohistochemical analysis dectected high expression of WNT-1 to be 
highly expressed in prostate cancer cell lines, primary tumours and 
metastases91. 
 An emerging theme is the activation of noncanonical WNT signalling in 
advanced prostate cancer and/or in CRPC. WNT-5a is upregulated in prostate 
cancer and can promote prostate tumour cell invasion through FZD2 and 
ROR292. Moreover, Wnt-5a haploinsufficiency in a mouse model of prostate 
cancer prevents the early onset and early lethality of prostate tumours93. 
However, some reports contradict the protumorigenic effect of WNT-5A, 
correlating high WNT-5A expression with improved outcomes in localized, low-
grade prostate cancer 94–96. In other cancers such as liver, breast and lung, the 
WNT-5A-FZD2 complex has been reported to associate with the protein 
tyrosine kinase FYN and signal transducer and activator of transcription 3 
(STAT3) to promote the epithelial–mesenchymal transition (EMT) and cell 
migration97. One possible explanation for the discrepancy is that the tumour-
suppressing role of WNT-5A results from inhibition of canonical signalling and 
its tumour-promoting role from activation of noncanonical signalling, consistent 
with association of increased expression of WNT5A and FZD2 with metastasis 
and biochemical recurrence98. Evidence exists that supports a role for WNT-5A 
in the development of resistance to ADT: WNT5A mRNA is found in circulating 
tumour cells (CTCs) from patients with CRPC 99 and from patients with prostate 
cancer whose disease progressed whilst they were undergoing treatment with 
the AR inhibitor enzalutamide100. WNT-7B, which had been previously 
observed to be upregulated in prostate cancer101, was shown to be an AR target 
gene in CRPC100. WNT-7B activates a noncanonical signal involving PKC and 
can induce an osteoblastic response in bone102. WNT-11 is also upregulated in 
prostate cancer, but, in contrast to WNT-7B, its expression is repressed by 
androgens103. WNT11 mRNA expression is elevated in tumours from patients 
receiving ADT104 and cell studies show that this WNT is required for prostate 
cancer cell invasion and neuroendocrine-like differentiation105. Many WNTs are 
observed to be upregulated in certain settings: mRNA expression of WNT5B, 
WNT6, WNT10A, and WNT16 is increased in tumours from patients after 
ADT106, and WNT2, WNT3A, and WNT11 mRNAs are induced by ERG78, an 
oncogene expressed in prostate cancer exhibiting TMPRSS2–ERG gene 
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fusion107,108.  
 ERG also induces expression of FZD3, FZD5, FZD7, and FZD8 mRNAs109, 
and also FZD4, which has a role in EMT110. Independent studies reported 
increased expression of FZD8111 and its closest relative, FZD5, in advanced 
prostate cancer90. In addition, SOX9, a critical effector of ERG, is required for 
increased expression of FZD7112, which is also upregulated in patients after 
ADT106. Evidence for increased expression of WNT coreceptors in prostate 
cancer is not as readily available as the evidence for that of the FZD family. 
However, ROR1 protein was shown to be expressed in 19 of 21 prostate 
tumours, as well as in many other types of cancer, such as lung, ovarian and 
colorectal, in which it is linked to increased AKT and CREB phosphorylation 
and increased proliferation113. Together, these studies highlight a limited 
number of WNTs and WNT receptors as potential therapeutic targets, 
particularly in the setting of CRPC. 
 
[H1] WNT signalling regulators 
 A common theme in prostate cancer is the loss of expression of genes that 
encode secreted factors that inhibit WNT signalling, usually through promoter 
methylation. These include genes that encode WNT binding proteins, such as 
WIF-1 (for which restoration of expression reduces tumour cell motility and 
reverses EMT114) and sFRP110,11 (expression of which inversely correlates with 
β-catenin expression and is a favourable predictive and prognostic biomarker 
in prostate cancer115). Another study showed reduced mRNA expression of 
SFRP1 and SFRP5 in prostate cancer but an increase in SFRP4116. SFRP2 
gene expression is also downregulated in prostate cancer by promoter 
methylation117,118. sFRPs do not always inhibit WNT signalling; for example,	
sFRP2 potentiates WNT-16B signalling to promote PC3 prostate cancer cell 
resistance to mitoxantrone, a genotoxic agent frequently administered to 
prostate cancer patients as a second-line therapy119. 
 Dickkopf proteins can be protumorigenic in some settings, despite their 
function as WNT inhibitors and the observation that they are frequently silenced 
in cancer by gene promoter methylation. In prostate cancer, high levels of DKK-
1 in serum are associated with poor patient prognosis120. Furthermore, 
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overexpression of DKK-1 promotes prostate tumour growth and the incidence 
of bone metastases121, and induces osteolytic lesions122. Some of the effects 
of DKK-1 have been interpreted in the context of its ability to inhibit canonical 
signalling, resulting in activation of noncanonical signalling. However, the 
discovery in 2016 of an unrelated receptor for DKK-1, cytoskeleton-associated 
protein 4 (CKAP4), indicates that DKK-1 can also enhance cell proliferation 
independently of its effects on WNT signalling123. 
 Among the other proteins that regulate WNT signalling at the cell surface, 
mutations in the ubiquitin ligases RNF43 and ZNRF3 and gene fusions that 
increase expression of RSPO2 were detected at an overall frequency of 6% in 
a panel of 150 metastatic CRPC tumours72, suggesting novel therapeutic 
options might be a possibility for some patients with prostate cancer. 
 
[H1] WNT and the tumour microenvironment 	The development and progression of cancer involves several signals that rely 
on the intrinsic properties of the tumour cells. However the interaction of cancer 
cells with other cell types in the tumour microenvironment, both in the primary 
tumour and at sites of metastasis, is also important124.   
 Prostate stromal cells secrete several WNT family members that can influence 
tumorigenesis and disease progression (Fig. 4). This secretion is exemplified 
by studies in mice showing that stromal Wnt-3a activates canonical Wnt 
signalling in the epithelium, facilitating progression of PIN lesions to 
adenocarcinoma and resistance to androgen deprivation125. Stromal 
overexpression of high mobility group protein HMGI-C in mice was observed to 
promote development of multifocal PIN lesions that were accompanied by 
increased expression of Wnt2, Wnt4, and Wnt9a, and could be suppressed by 
overexpression of sFRP1 and Dkk1126. WNT10B is among the genes 
upregulated in human prostate cancer stroma, and silencing it reduces the 
protumorigenic effects of stromal cells on LNCaP tumour growth in xenograft 
assays127. WNT signals from the tumour microenvironment are also involved in 
the development of resistance to therapy. Therapy-induced DNA damage 
increases the expression of WNT-16B in prostate fibroblasts128, in which it acts 
in a paracrine manner to activate canonical WNT signalling in tumour cells and 
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promotes therapy resistance and disease progression128. Further studies are 
required to determine the importance of stromal-derived  WNT-16B and of other 
WNT family members, such as WNT-5A129, at different stages of prostate 
cancer. 
 
[H1] WNT signalling and cancer stem cells 
 In prostate and other cancers, such as breast, pancreas, colon, lung and brain, 
the cancer stem (or progenitor) cell (CSC) population shares many 
characteristics with somatic stem cells, such as immortality and self-renewal, 
and is believed to be a source of tumour-initiating cells and also responsible for 
tumour recurrence, metastasis, and chemoresistance130,131. WNT–b-catenin 
signalling was shown to promote prostate CSC renewal and expansion in 
2009132. In 2015, one study showed that shRNA-mediated silencing of the 
tumour suppressor gene DAB2IP (disabled homolog 2-interacting protein) in 
human prostate epithelial cells generated CSC with activated WNT–b-catenin 
signalling133. In this model, WNT–b-catenin signals directly induced expression 
of the stem cell marker gene CD44, and inhibitors of WNT secretion synergized 
with docetaxel to inhibit tumour growth in vivo133. In addition, the mRNA and 
protein expression of ALDH1A, another CSC marker that is also a direct target 
of WNT–b-catenin signalling, is elevated in radioresistant prostate cancer 
cells134. Inhibition of WNT–b-catenin signalling using the tankyrase inhibitor 
XAV939 or siRNA-mediated knockdown of β-catenin	reduced ALDH1A mRNA 
and protein levels, reduced the population of ALDH-positive CSCs and 
increased cancer cell sensitivity to irradiation134. These results provide rationale 
for using inhibitors of WNT–b-catenin signalling to target prostate CSCs and 
thereby reduce the development of tumour resistance to therapy 135. 
 
[H1] Targeting WNT signalling 
 The variety of changes observed in WNT pathway components has the 
potential to provide therapeutic opportunities, particularly in advanced prostate 
cancer. Several drugs that target WNT signalling are in development (Fig. 5), 
but very few of them are being tested for the treatment of prostate cancer136. 
This omission might reflect a general impression that WNT signalling has a 
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minor role in prostate cancer, based on the low frequency of WNT pathway 
mutations in primary tumours. The higher frequency of APC mutations, 
identification of novel mutations in CRPC, and the increasing evidence that 
noncanonical WNT signals are active in prostate cancer, are expected to 
stimulate further interest in this area of drug development. 
 Specific inhibitors of WNT signalling have been investigated and several FDA-
approved drugs in current use affect WNT–b-catenin signalling137, and at least 
one of these — aspirin — is associated with reduced prostate cancer risk138. 
Specific WNT pathway inhibitors can be classified into functional groups: 
inhibition of WNT secretion, regulation of antagonists and agonists,	targeting 
WNT receptor interactions, preventing DVL activation, stabilizing the 
destruction complex and	targeting nuclear b-catenin partners. 
[H2] Inhibition of WNT secretion 
Porcupine, a membrane-bound O-acetyltransferase, is uniquely responsible for 
WNT palmitoylation of WNT proteins, which is essential for their secretion139. 
Targeting porcupine has been used extensively to inhibit WNT signalling in 
different cancer types. The first reported porcupine inhibitors, Inhibitors of WNT 
Production	 (IWPs, the best known of which is IWP-2), were identified in a 
synthetic chemical screen140. Several other porcupine inhibitors have since 
been reported. These inhibitors include WNT-C59, which inhibits growth of 
WNT-1-expressing mammary tumours in mice141; LGK974142, an orally 
bioavailable inhibitor that reduces tumour growth in rodent models of breast 
cancer, head and neck cancer142, and of xenografts of pancreatic tumours with 
RNF43 mutations143; and ETC-159, another orally bioavailable molecule, which 
inhibits growth of	patient-derived xenografts of colorectal cancers with RSPO 
fusions144. WNT974 (previously known as LGK974) entered a phase I trial in 
2011 (still ongoing), for patients with tumours that have mutations in RNF43 
and ZNRF3 or RSPO gene fusions12. Preliminary clinical data suggested 
WNT974 has a manageable safety profile and potential for anti-tumour 
activity145. An ongoing phase I/II trial is using WNT974 in combination with the 
RAF inhibitor LGX818 and the EGFR inhibitor Cetuximab  in patients with 
BRAFV600-mutant KRAS wild-type metastatic colorectal cancer harboring 
RNF43 mutations or RSPO fusions13. ETC-159 (longer name ETC-1922159) 
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has also entered a phase I trial in patients with advanced solid tumours14 and 
preliminary data indicate that it is safe and well-tolerated and dose escalation 
is ongoing146 (Table 2). The identification of RNF43 and ZNRF3 mutations and 
RSPO2 gene fusions in CRPC72 in 2015 provides hope that porcupine inhibitors 
might also be assessed in patients with advanced prostate cancer. 
[H2] Regulation of antagonists and agonists 
 Many secreted WNT antagonists are epigenetically silenced in cancer, and 
drugs that target the epigenetic machinery can restore their expression. For 
example, treatment of renal cancer cells or breast cancer cells with	combined 
therapy of the histone deacetylase (HDAC) inhibitor romidepsin and the DNA 
methyltransferase (DNMT) inhibitor decitabine reactivates SFRP1 expression 
to inhibit growth and induce apoptosis in an sFRP1-dependent manner147. 
Application of recombinant sFRP1 proteins could also be a therapeutic 
option148, as is the case for DKK-3, which preclinical studies have shown is an 
effective treatment for prostate cancer and other cancers, including breast 
cancer, gastric carcinoma and malignant mesothelioma149. A phase I/II clinical 
trial started in 2013 using an adenoviral vector expressing DKK-3 in patients 
with localized prostate cancer15 have reported promising results, showing 
reduced metastatic tumour growth in a case study of a patient with treatment-
resistant disease and anti-tumour activity and reduced biochemical recurrence-
free survival in patients with high-risk localised prostate cancer150,151 (Table 2).. 
Another approach to targeting tumours that contain RSPO fusions is to use 
function-blocking antibodies; as has been done for RSPO3 in colorectal 
cancer152. RSPO3 antibodies (OMP131R10) are now in phase I clinical trials 
for advanced solid tumours and metastatic colorectal cancer with results 
expected in 201816 (Table 2). 
[H2] Targeting WNT receptor interactions 
 WNT ligands and their receptors are attractive targets for therapy because they 
are accessible to monoclonal antibodies and small molecules153. WNT-5A has 
been targeted using antibodies and a WNT-5A-derived peptide called Foxy-5. 
The WNT-5A antibodies reduce metastasis of gastric tumour cells154 but have 
not been tested for their effects on prostate cancer metastasis. These 
antibodies do not block WNT receptor binding, but they inhibit WNT-5A-induced 
internalization of FZD2 and ROR2155. Foxy-5 is a formylated hexapeptide that 
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inhibits breast cancer metastasis156,157. The first phase I trial failed to reach a 
maximum tolerated dose17, so a second trial is recruiting patients with 
metastatic breast, colon, or prostate cancer18 (Table 2). Given that the 
antibodies inhibit WNT-5A signalling and Foxy-5 activates it, and in light of the 
contrasting reports on the prognosis of high WNT-5A expression in prostate 
cancer, stratifying patients before using treatments that target WNT-5A will be 
important. 
 Antibodies are not the only tool for targeting WNT proteins: a recombinant 
fusion of the ligand-binding domain of FZD8 and the crystallisable fragment 
domain of a human IgG1 (FZD8-Fc, also known as OMP-54F28 and Ipafricept) 
is a decoy WNT receptor that inhibits the proliferation of CSCs and induces 
tumour differentation158. In a phase Ia clinical trial, this drug was well tolerated 
and demonstrated evidence of Wnt pathway modulation and potential early 
single-agent activity manifested by prolonged stable disease19,159. It is now 
being trialled in combination with other drugs in ovarian 20,160, liver21 and 
pancreatic cancer22 (Table 2). 
 The success of porcupine inhibitors in blocking all WNTs and the possibility of 
redundancy among members of the WNT family in cancer has led to increased 
efforts to target WNT receptors, rather than WNT proteins. FZD7 is one of most 
frequently upregulated WNT receptors in many cancers, including intestinal 
cancer, hepatocellular carcinoma, gastric cancer and breast cancer, and it has 
been targeted using both decoy receptor and antibody approaches161. 
Vantictumab (OMP-18R5) targets FZD1, FZD2, FZD5, FZD7, and FZD8. In 
preclinical models, it reduces CSC frequency and induces differentiation of 
tumorigenic cells to cell types that are less tumorigenic and/or more susceptible 
to conventional chemotherapy. It exhibits strong anti-tumour activity in 
combination with other approved therapies in patient-derived xenograft (PDX) 
models, including cancers of the pancreas, breast, lung, liver, ovary and 
colon162. Phase Ib clinical trials of vantictumab in combination with standard-of-
care chemotherapy have been carried out in HER2-negative breast cancer and 
advanced pancreatic cancer23–26 (Table 2). In 2017, vantictumab and ipafricept 
were shown to potentiate the effects of taxanes in PDX models. This involved 
sensitization of cancer cells to taxanes and required treatment with WNT 
inhibition prior to mitotic blockade with paclitaxel163. This combination strategy 
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has been incorporated into ongoing clinical trials of ipafricept and vantictumab 
with other chemotherapeutic agents20,22,25,26. 
 Other FZD antibodies are patented for the treatment of cancer, for example 
there were plans to test OTSA101, a radiolabelled antibody against FZD10164, 
in phase I trials for synovial sarcoma was found to be feasible and safe but the 
number of patients accrued was too small to continue the study27,165 (Table 2). 
In 2016, phage display was used to generate antibodies that recognise FZD5 
and FZD8 that inhibit the growth of RNF43-mutant pancreatic tumour cells in 
vivo166. 
 Among the non-FZD family receptors being targeted for therapy, LRP6 and 
ROR1 might be relevant to prostate cancer. The antihelminthic drug 
niclosamide has been reported to induce apoptosis in prostate cancer by 
targeting LRP6167. However, this therapy was also shown to downregulate 
oncogenic variants of AR and overcome enzalutamide resistance in 
CRPC168,169, so whether its effects relate to LRP6 or AR, or both, is unclear. 
Other agents that target LRP6 exist and can affect prostate cancer cells, 
including salinomycin, which induces LRP6 degradation170, and Mesd, which 
acts as a chaperone for LRP5 and LRP6 and inhibits prostate tumour xenograft 
growth171. ROR1 expression is increased in a number of cancers, including 
prostate cancer 113,172. Given the importance of ROR1 in chronic lymphocytic 
leukaemia, a variety of approaches have been used to target it, including 
antibodies, chimeric antigen receptor T cells, and antibody–drug conjugates173. 
Among the antibodies, UC-961 (cirmtuzumab) is recruiting patients for phase I 
clinical studies for chronic lymphocytic leukaemia28–30 and breast cancer31 
(Table 2). 
[H2] Preventing DVL activation 
 The DVL PDZ domain binds to the carboxyl terminal region of FZD receptors 
and is essential for signal transduction. Among the three DVL family members, 
DVL2 is upregulated in prostate tumours and silencing it inhibits prostate 
cancer cell proliferation and migration174. A number of DVL inhibitors have been 
reported, one of which has been shown to inhibit proliferation of the prostate 
cancer cell line PC-3175. 
[H2] Stabilizing the destruction complex 
	 18	
 Tankyrases 1 and 2 are poly (ADP-ribose) transferases (PARPs) that target 
axin1 and axin2 for proteasomal degradation. Their inhibitors are widely used 
to promote b-catenin degradation, thereby inhibit canonical WNT signalling176. 
Several structurally distinct tankyrase inhibitors are now being developed for 
possible clinical use. Structure-based optimization of one of these, XAV939, 
resulted in the development of a more selective and orally bioavailable inhibitor, 
NVP-TNKS656, which inhibited WNT signalling in mouse mammary tumour 
virus (MMTV)–WNT-1 tumour-bearing mice177. Evidence exists that chronic 
WNT stimulation, which increases expression of the b-catenin partners LEF1 
and B-cell CLL/lymphoma 9-like protein (BCL9L), renders tumour cells resistant 
to tankyrase inhibition because they shield b-catenin from axin178. This 
shielding might occur in prostate tumours that express high levels of LEF179. 
Finally, it should be noted that tankyrase inhibitors might have effects not 
directly related to WNT signalling, as tankyrases bind and regulate several 
other proteins, including PTEN and angiomotin (AMOT) family 
proteins176,179,180.  
[H2] Targeting nuclear b-catenin partners 
 Transcriptional activation by b-catenin requires interaction both with TCF/LEF 
family transcription factors and other coactivators, such as CBP or p300, which 
associate with the carboxyl terminal transactivation domain in b-catenin. Thus, 
the disruption of these interactions might provide new therapies. Small 
molecule inhibitors of β-catenin-responsive transcription have been identified 
that disrupt the β-catenin–TCF4 interaction, including the inhibitors of catenin 
responsive transcription (iCRTs)181, BC21, which was identified by virtual 
docking studies using a compound library and the crystal structures of β-catenin 
alone and in complexes with TCF3 and TCF4182, and LF3, a 4-thioureido-
benzenesulfonamide derivative identified in a high-throughput screen of 16,000 
compounds183. In 2004 , ICG-001, a first-in-class modulator of WNT signalling, 
was observed to inhibit binding of β-catenin to CBP184, and a derivative, PRI-
724, is in phase I clinical trials in different solid tumors32 and has been reported 
to have an acceptable toxicity profile185. Results are anticipated from completed 
phase I trials in patients with pancreatic cancer33 and leukemia34 (Table 2). In 
addition, a compound named Windorphen has been identified that prevents 
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p300 binding to β-catenin and reduces the viability of PC3 and DU145 cells in 
vitro186. Both CBP and p300 have many other partners, so these compounds 
also have WNT-independent effects that can lead to induction of caspase-3 
dependent apoptosis and cell-cycle arrest187. Two further inhibitors that affect 
b-catenin-dependent transcription are triptonide, a small molecule identified 
from the traditional Chinese medicine	Tripterygium wilfordii that targets the C-
terminal domain of β-catenin188, and an	orally bioavailable WNT inhibitor that 
acts at or downstream of TCF, identified in a cell-based screen189. The former 
has been shown to promote apoptosis of cancer cells, including PC3 and 
DU145 prostate cancer cells188 and the later inhibited tumour growth in a colon 
cancer xenografts189, suggesting they have therapeutic potential. 
 Given the number of studies on the interaction between b-catenin with AR, the 
fact that no drug screens targeting this complex have been performed is 
surprising. However, a group of investigators used the overlap of the interaction 
domains of AR and TCF-4 on β-catenin and observed that iCRT3181 inhibited 
both AR and WNT–b-catenin signalling and reduced prostate tumour growth in 
vivo190. The effect of iCRT3 on AR binding to target genes was accompanied 
by a reduction in binding of coactivator-associated arginine methyltransferase 




 WNT signalling has fundamental roles in prostate carcinogenesis. Both 
autocrine signalling in tumour cells and paracrine signalling from the tumour 
microenvironment are involved in prostate tumorigenesis, metastasis, and 
therapy resistance. Given the possibility that drugs that specifically target  WNT 
signalling components will reach the clinic, the question that arises is whether 
canonical or noncanonical WNT signals are more critical in prostate cancer. 
The answer might be tumour stage-dependent and context dependent. 
Canonical WNT signals could be more important to support prostate cancer 
stem (or progenitor) cell proliferation and/or survival, than noncanonical signals, 
particularly under conditions of androgen deprivation, whereas noncanonical 
WNT signals, by endowing tumour cells with migratory and/or invasive 
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properties, might be more important at early stages of tumour spread. Both 
could be critical in metastatic CRPC, in which both activating mutations in 
canonical WNT signalling and activated noncanonical WNT signalling have 
been observed. Several agents that target WNT signalling at different levels of 
the pathway have been developed, and some of these have reached clinical 
trials (Table 2). However, not many of them have been tested as possible 
therapies for prostate cancer. Mutations in CTNNB1 and APC are relatively 
infrequent in primary tumours, but they are more prevalent than originally 
thought in advanced tumours and CRPC, and are accompanied by increased 
noncanonical WNT signalling. In addition, novel WNT pathway mutations have 
been discovered in CRPC. Together, these new discoveries provide hope for a 
subset of patients who might benefit from drugs currently in clinical trials that 
inhibit WNT signalling, particularly those affecting WNT secretion and/or WNT 
receptor binding, as well as those preventing b-catenin interaction with key 
transcription factors, such as LEF1 and AR.  
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Figure 1 |	 WNT signalling pathways. In the absence of WNT ligands (WNT 
OFF), b-catenin is recruited and degraded by the destruction complex 
(adenomatous polyposis coli protein (APC), axin, glycogen synthase kinase-3 
(GSK-3) and casein kinase 1 (CK1)) and yes-associated protein (YAP) and 
transcriptional coactivator with PDZ-binding motif (TAZ)), which have been 
linked to WNT signalling, and WNT target genes are repressed. Binding of 
WNT ligands to frizzled (FZD) and either LRP5 or LRP6 to activate canonical 
signalling or ROR1, ROR2, RYK, PTK7 or MuSK to activate and noncanonical 
signalling (WNT ON). Canonical signals disrupt the destruction complex, 
stabilizing b-catenin, which enters the nucleus and binds T-cell factor/lymphoid 
enhancer-binding factor 1 (TCF/LEF) family transcription factors to activate 
gene expression. The WNT–STOP pathway is a transcription-independent 
pathway involving low-density lipoprotein receptor (LRP) and cyclin Y. 
Noncanonical signals activate small GTPases and various kinases, mobilize 
Ca2+ and activate activator protein 1 (AP-1) family and nuclear factor of 
activated T-cells (NFAT) transcription factors. New noncanonical signals 
involve activation of YAP and TAZ, the SRC family tyrosine protein kinase 
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Figure 2 Crystal structure of Wnt8-FZD8 CRD complex  
Representative image of Xenopus wnt8 (purple) bound to FZD8-CRD (blue). The 
interaction is mediated through the lipid thumb (“Site 1”) and the index finger (“Site 2”) 
of wnt8. Sites 1 and 2 are involved in Wnt-FZD promiscuity or specificity, respectively. 
Patch residues are involved in wnt binding to coreceptors leading to ternary 


























Figure 3 | WNT signalling regulation by RNF43, ZNRF3 and RSPO. RNF43 
and ZNRF3 ubiquitin ligases inhibit WNT signalling by ubiquitinating frizzled (FZD) 
receptors, promoting their degradation. R-spondin (RSPO) binds	 RNF43 and/or 
ZNRF3 and leucine-rich repeat-containing G protein-coupled receptors (LGR5), 
resulting in membrane clearance of RNF43 and ZNRF3 and increased FZD stability. 
Mutations in RNF43 and ZNRF3 or overexpression of RSPO as a result of a RSPO 
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Figure 4 | Paracrine  WNT signals from the tumour microenvironment. 
Paracrine WNT signals from the tumour microenvironment can contribute to tumour 
progression (WNT-10B100) and therapy resistance (SFRP291 and WNT-16B101 or  
WNT-5A and bone morphogenetic protein (BMP) 6 102). 		 	
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Figure 5 | Drugs that target WNT signalling. May drugs have been developed 
that act on different targets at different levels in the WNT signalling pathway. The 
therapeutics are inhibitors of WNT secretion (red), regulators of WNT antagonist and 
antagonist function (blue), drugs that target WNT receptor interactions (green), drugs 
that prevent dishevelled (DVL) activation (pink), drugs that stabilize the destruction 
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Table 1 | Key changes in  WNT signalling pathway components in 








Disease stage Effect on WNT signalling, and/or on 



















Disease progression (mice) 
Decreased PSA-free survival 47, 48 
Ligands    
 WNT5A Upreg
ulation 
CTCs from CRPC72 
and ADT73 patients 
with tumours66,74 and 
metastases74 
Localized cancer 
Noncanonical: increased CRPC growth, bone 
metastasis; metastasis and recurrence71 




CTCs from patients 
receiving ADT73  











Tumour stroma101 Canonical; therapy resistance101 
Recepto
rs 














Tumours111 Canonical and noncanonical 
ROR1 Upreg
ulation 
Tumours86 Noncanonical; not known 
Regulat
ors 




Tumours 88, 89 Reduced survival88 
SFRP2 Upreg
ulation 




Serum93, tumours64  Increased tumour growth, bone metastases94 
and osteolytic lesions95 in mice; poor 



















CRPC46 Potentiation of  WNT signals 
APC, adenomatous polyposis coli protein; CRPC, castration-resistant prostate cancer; DKK, 
Dickkopf-related protein; FZD, frizzled; ROR, tyrosine-protein kinase transmembrane 
receptor; RSPO, R-spondin; SFRP, secreted frizzled-related protein 	
Table 2 |  WNT pathway inhibitors in clinical trials 
 
 
Inhibitor Target Clinical trial Phase Ref 
Inhibition of Wnt secretion         
LGK974 (also known as WNT974) Porcupine NCT01351103 I 12,145 
    NCT02278133 I/II 13 
ETC-159 (also known as ETC-1922159) Porcupine NCT02521844 I 14,146 
Regulation of antagonists and agonists         
Adenovirus expressing DKK3 (also known as REIC)  not defined NCT01931046 I/II 15 
OMP131R10 RSPO3 NCT02482441 I 16 
Targeting WNT receptor interactions         
FOXY-5 WNT5A receptors  NCT02020291 I 17 
   NCT02655952 I 18 
OMP-54F28 (Ipafricept) WNT family NCT01608867 I 19,159 
    NCT02092363 I 20,160 
    NCT02069145 I 21 
    NCT02050178 I 22 
OMP-18R5 (Vantictumab) FZD1,2,5,7,8 NCT01345201 I 23 
   NCT01957007 I 24 
   NCT01973309 I 25 
   NCT02005315 I 26 
OTSA101 FZD10 NCT01469975 I 27,165 
UC-961 (Cirmtuzumab) ROR1 NCT02222688 I 28 
    NCT02860676 I 29 
    NCT03088878 I/II 30 
    NCT02776917 I 31 
Targeting nuclear b-catenin partners         
PRI-724 CBP NCT01302405 I 32,185 
    NCT01764477 I 33 
    NCT01606579 I/II 34 
CBP, CREB-binding protein; DKK, Dickkopf-related protein; FZD, frizzled; ROR, tyrosine 
protein kinase transmembrane receptor; RSPO, R-spondin; SFRP, secreted frizzled-related 
protein 
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